A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Keynote-252 / ECHO-301
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 31 Mar 2017 This trial is being conducted under the expanded collaboration for seven pivotal trials of Epacadostat and KEYTRUDA (pembrolizumab) between an Incyte Corporation and Merck, as reported in an Incyte Corporation media release.
    • 08 Jul 2016 Last checked against United Kingdom Clinical Research Network record.
    • 22 Jun 2016 According to a Incyte Corporation media release, the first patient has been treated in this study, and initial data is expected to be available in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top